Dexcom (DXCM)

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-09-10 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: DEXCOM INC (DXCM) CIK: 0001093557 --- Reporting Owner --- Name: Boehnlein Glenn S CIK: 0001670936 Role: Director --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-09-10 | Code: A (Grant or award) Shares: +5,841 | Price: $0.00 Shares Owned After: 5,841 | Ownership: D (Direct) Footnotes: [F1] Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. --- Holdings --- [Holding #1] Security: Common Stock Ownership: I (Indirect) Footnotes: [F2] Shares are held by the Boehnlein 2017 Trust, with respect to which the Reporting Person and the Reporting Person's spouse are co-trustees. --- Footnotes (Complete Index) --- F1: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2: Shares are held by the Boehnlein 2017 Trust, with respect to which the Reporting Person and the Reporting Person's spouse are co-trustees. --- Signature --- /s/ /s/ Jereme M. Sylvain, as Attorney-in-Fact for Glenn S. Boehnlein (2026-09-10)